The Experts below are selected from a list of 1035 Experts worldwide ranked by ideXlab platform
Jy Drowley - One of the best experts on this subject based on the ideXlab platform.
-
SCCM & Windows 10 SOE
2017Co-Authors: Jy DrowleyAbstract:System Center Configuration manager simplify's the management and migration of existing devices to Win 10 SCCM manages the deployment of system updates and endpoint Virus Protection. Microsoft SCCM will become the platform for Federation University to manage the deployment of the new Windows 10 SOE for students while enabling "BYOD" Bring Your Own Device alternative models for device deployment & management.
-
sccm windows 10 soe
2017Co-Authors: Jy DrowleyAbstract:System Center Configuration manager simplify's the management and migration of existing devices to Win 10 SCCM manages the deployment of system updates and endpoint Virus Protection. Microsoft SCCM will become the platform for Federation University to manage the deployment of the new Windows 10 SOE for students while enabling "BYOD" Bring Your Own Device alternative models for device deployment & management.
Robert Parks - One of the best experts on this subject based on the ideXlab platform.
-
zika Virus Protection by a single low dose nucleoside modified mrna vaccination
Nature, 2017Co-Authors: Norbert Pardi, Michael J Hogan, Rebecca S Pelc, Hiromi Muramatsu, Hanne Andersen, Christina R Demaso, Kimberly A Dowd, Laura L Sutherland, Richard M Scearce, Robert ParksAbstract:A single, low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA encoding the pre-membrane and envelope glycoproteins of Zika Virus protects both mice and rhesus macaques against infection and elicits rapid and long-lasting neutralizing antibody responses. Public health efforts to combat Zika Virus disease are hampered by lack of a safe and efficient vaccine. Drew Weissman and colleagues report the development of a candidate vaccine that is based on chemically stabilized messenger RNA (mRNA) that encodes the premembrane and envelope glycoproteins of the Zika Virus. This mRNA is packaged into lipid nanoparticles that can be delivered intradermally. A single dose of the vaccine gave mice and rhesus macaques long-term immunity to the Zika Virus. These findings pave the way for the development of candidate vaccines that could protect humans against Zika Virus disease. Zika Virus (ZIKV) has recently emerged as a pandemic associated with severe neuropathology in newborns and adults1. There are no ZIKV-specific treatments or preventatives. Therefore, the development of a safe and effective vaccine is a high priority. Messenger RNA (mRNA) has emerged as a versatile and highly effective platform to deliver vaccine antigens and therapeutic proteins2,3. Here we demonstrate that a single low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA (mRNA–LNP) encoding the pre-membrane and envelope glycoproteins of a strain from the ZIKV outbreak in 2013 elicited potent and durable neutralizing antibody responses in mice and non-human primates. Immunization with 30 μg of nucleoside-modified ZIKV mRNA–LNP protected mice against ZIKV challenges at 2 weeks or 5 months after vaccination, and a single dose of 50 μg was sufficient to protect non-human primates against a challenge at 5 weeks after vaccination. These data demonstrate that nucleoside-modified mRNA–LNP elicits rapid and durable protective immunity and therefore represents a new and promising vaccine candidate for the global fight against ZIKV.
Yan Chen - One of the best experts on this subject based on the ideXlab platform.
-
Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and its control of HBV replication
Chinese Journal of Hepatology, 2011Co-Authors: Jun Wu, Mingfa Chen, Chun-yan Zhang, Yan ChenAbstract:OBJECTIVE: This report aims to investigate the Toll-like receptor (TLR) signaling pathways and induced antiviral activity in hepatocytes. METHODS: We isolated primary hepatocytes from wild-type C57BL/6 mice and examined the expression of TLR by realtime RT-PCR. Hepatocytes were stimulated with TLR 1-9 agonists and the supernatants were harvested. The secretion of cytokines were tested by ELISA. The antiviral effectors in supernatants were assayed via Virus Protection assay (in EMCV system) and the control of HBV replication were assessed via Southern blotting (in HBV system). RESULTS: We demonstrated that hepatocytes expressed TLR1-9. In accordance with these TLR expression profiles, hepatocytes responded to all TLR ligands by producing inflammatory cytokines (TNF-α or IL-6), to TLR -1,-3,-7 and -9 ligands by producing type I IFN (IFN-α or IFN-β). Only TLR 3 and TLR 7 agonists could stimulate the production of high amounts of antiviral mediators by hepatocytes in Virus Protection assay. By contrast, supernatants from TLR1, -3 and -4 directly stimulated hepatocytes and TLR 3, -7 and -9 transfected hepatocytes were able to potently suppress HBV replication. CONCLUSION: Primary hepatocytes display a unique TLR signaling pathway and can control HBV replication after stimulation by TLR agonists in mice. It may be helpful for the development of TLR-based therapeutic approaches against hepatotropic Virus.
-
Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and its control of HBV replication
Chinese Journal of Hepatology, 2011Co-Authors: Jun Wu, Mingfa Chen, Chun-yan Zhang, Yan ChenAbstract:Objective This report aims to investigate the Toll-like receptor (TLR) signaling pathways and induced antiviral activity in hepatocytes.Methods We isolated primary hepatocytes from wild-type C57BL/6 mice and examined the expression of TLR by realtime RT-PCR.Hepatocytes were stimulated with TLR 1-9 agonists and the supeernatants were harvested.The secretion of cytokines were tested by ELISA.The antiviral effectors in supematants were assayed via Virus Protection assay (in EMCV system) and the control of HBV replication were assessed via Southern blotting (in HBV system).Results We demonstrated that hepatocytes expressed TLR1-9.In accordance with these TLR expression profiles,hepatocytes responded to all TLR ligands by producing inflammatory cytokines ( TNF-α or IL-6 ),to TLR -1,-3,-7 and -9 ligands by producing type I IFN ( IFN-α or IFN-β ).Only TLR 3 and TLR 7 agonists could stimulate the production of high amounts of antiviral mediators by hepatocytes in Virus Protection assay.By contrast,supernatants from TLR1,-3 and -4 directly stimulated hepatocytes and TLR 3,-7 and -9 transfected hepatocytes were able to potently suppress HBV replication.Conclusion primary hepatocytes display a unique TLR signaling pathway and can control HBV replication after stimulation by TLR agonists in mice.It may be helpful for the development of TLR-based therapeutic approaches against hepatotropism Virus. Key words: Hepatocytes; Toll-like receptor; Immunity, natural; Hepatitis B Virus
Ray Stanton - One of the best experts on this subject based on the ideXlab platform.
-
Winning security policy acceptance
Computer Fraud & Security, 2006Co-Authors: Mark Hughes, Ray StantonAbstract:There are very few organizations today that haven't adopted at least some form of information security measures. The majority have firewalls and anti-Virus Protection and most will conduct regular backups of data, run anti-spam software and have policies for acceptable use of emails and the Internet. VPNs, secure mobile working, intrusion Protection and detection and business continuity plans have all seen growing levels of deployment, indicating that security is being taken seriously at board level at companies of all sizes. As a result, many of these companies feel confident in their ability to protect themselves. But that confidence is often misplaced.
-
Winning security policy acceptance
Computer Fraud and Security, 2006Co-Authors: Mark Hughes, Ray StantonAbstract:There are very few organizations today that haven't adopted at least some form of information security measures. The majority have firewalls and anti-Virus Protection and most will conduct regular backups of data, run anti-spam software and have policies for acceptable use of emails and the Internet. VPNs, secure mobile working, intrusion Protection and detection and business continuity plans have all seen growing levels of deployment, indicating that security is being taken seriously at board level at companies of all sizes. As a result, many of these companies feel confident in their ability to protect themselves. But that confidence is often misplaced. ?? 2006 Elsevier Ltd. All rights reserved.
Norbert Pardi - One of the best experts on this subject based on the ideXlab platform.
-
zika Virus Protection by a single low dose nucleoside modified mrna vaccination
Nature, 2017Co-Authors: Norbert Pardi, Michael J Hogan, Rebecca S Pelc, Hiromi Muramatsu, Hanne Andersen, Christina R Demaso, Kimberly A Dowd, Laura L Sutherland, Richard M Scearce, Robert ParksAbstract:A single, low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA encoding the pre-membrane and envelope glycoproteins of Zika Virus protects both mice and rhesus macaques against infection and elicits rapid and long-lasting neutralizing antibody responses. Public health efforts to combat Zika Virus disease are hampered by lack of a safe and efficient vaccine. Drew Weissman and colleagues report the development of a candidate vaccine that is based on chemically stabilized messenger RNA (mRNA) that encodes the premembrane and envelope glycoproteins of the Zika Virus. This mRNA is packaged into lipid nanoparticles that can be delivered intradermally. A single dose of the vaccine gave mice and rhesus macaques long-term immunity to the Zika Virus. These findings pave the way for the development of candidate vaccines that could protect humans against Zika Virus disease. Zika Virus (ZIKV) has recently emerged as a pandemic associated with severe neuropathology in newborns and adults1. There are no ZIKV-specific treatments or preventatives. Therefore, the development of a safe and effective vaccine is a high priority. Messenger RNA (mRNA) has emerged as a versatile and highly effective platform to deliver vaccine antigens and therapeutic proteins2,3. Here we demonstrate that a single low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA (mRNA–LNP) encoding the pre-membrane and envelope glycoproteins of a strain from the ZIKV outbreak in 2013 elicited potent and durable neutralizing antibody responses in mice and non-human primates. Immunization with 30 μg of nucleoside-modified ZIKV mRNA–LNP protected mice against ZIKV challenges at 2 weeks or 5 months after vaccination, and a single dose of 50 μg was sufficient to protect non-human primates against a challenge at 5 weeks after vaccination. These data demonstrate that nucleoside-modified mRNA–LNP elicits rapid and durable protective immunity and therefore represents a new and promising vaccine candidate for the global fight against ZIKV.
